MarginsXMarginsX
Home › Markets › Health Care › ARGX

argenx SE (ARGX)

ARGX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$950.95
-0.95% on the day
Market cap
$59.0B
Large cap
Revenue · 2023
$35.5M
+254.4% on 2022
Net income · 2023
-$295.1M
-830.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/1697862/000155837024003665/0001558370-24-003665-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2023-12-31.

Profile

FieldValue
TickerARGX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryNetherlands
IPO year2017
SEC CIK0001697862
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inNetherlands

Financials · 2023

LineValue
Revenue$35.5M
Net income-$295.1M
Operating income-$425.0M
Net margin-830.4%
Operating margin-1196.2%
Revenue growth+254.4%
Cash$2.0B
Total assets$4.5B
P/E (computed)Net income was not positive
P/S (computed)1661.0×

Warning signs

Cash runway
Cash-flow positive
$3.5B cash at December 31, 2025
Share count, 1 year
+1.8%
2024-12-31 to 2025-12-31 · +11.7% over 3 years
Going-concern doubt
No
20-F filed March 19, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-19
Cash and burn$3.5B cash; operating cash flow $171.3M a quarter.Report 2025-12-31
Shares outstanding61,883,306 (2025-12-31); 60,760,957 a year earlier; 55,395,856 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorEY Accountants B.V., Eindhoven, NetherlandsPCAOB Form AP 2026-04-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed$1.3B$685.2M$3.5BNo debt tagsNeeds four quarters20-F 2026-03-19
FY 2024
2024-12-31
Not filed$833.0M-$82.7M$1.5BNo debt tagsNeeds four quarters20-F 2026-03-19
FY 2023
2023-12-31
$35.5M-$295.1M-$420.3M$2.0B$7.2M$35.5M20-F 2024-03-21
FY 2022
2022-12-31
$10.0M-$709.6M-$862.8M$800.7MNo debt tags$10.0M20-F 2024-03-21
FY 2021
2021-12-31
$497.3M-$408.3M-$606.8M$1.3BNo debt tags$497.3M20-F 2024-03-21
FY 2020
2020-12-31
$41.2M-$608.5M-$398.5M$1.2BNo debt tags$41.2M20-F 2023-03-16
FY 2019
2019-12-31
$78.5M-$181.2M$151.6M$372.2MNo debt tags$78.5M20-F 2022-03-21
FY 2018
2018-12-31
$21.5M-$66.6MNot filed$321.8MNo debt tags$21.5M20-F 2019-03-26

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52023-07-20
Latest annual report20-F2026-03-19
Latest quarterly / interim
FORM 6-K
6-K2026-11-09

Source: SEC EDGAR submissions feed, 298 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.5%
1 month+19.6%
3 months+12.0%
Year to date+14.2%
1 year+7.7%
From 52-week high-9.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
MRNAModerna Inc.$215.27-3.63%$87.1B
BIIBBiogen Inc.$251.65-0.69%$37.2B
RVMDRevolution Medicines Inc.$166.87-3.15%$36.1B
BNTXBioNTech SE American Depositary Share$85.26-0.40%$21.4B
GILDGilead Sciences Inc.$167.58-0.30%$207.9B
NBIXNeurocrine Biosciences Inc.$165.31-1.25%$16.7B
EXELExelixis Inc.$67.10-2.75%$16.4B
AMGNAmgen Inc.$462.32-0.72%$250.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier